tiprankstipranks
Advertisement
Advertisement

SVRA Stock Latest News

Savara reports Q1 EPS (15c), consensus (14c)
The FlySavara reports Q1 EPS (15c), consensus (14c)
2d ago
SVRA
Savara assumed with an Outperform at Oppenheimer
PremiumThe Fly
Savara assumed with an Outperform at Oppenheimer
21d ago
SVRA
Savara says FDA extended review for Molgramostim BLA
PremiumThe Fly
Savara says FDA extended review for Molgramostim BLA
29d ago
SVRA
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
PremiumRatings
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
1M ago
SVRA
Savara announces MHRA accepted submission of Molbreevi MAA
PremiumThe Fly
Savara announces MHRA accepted submission of Molbreevi MAA
1M ago
SVRA
Savara announces EMA validation of MAA for MOLBREEVI
PremiumThe FlySavara announces EMA validation of MAA for MOLBREEVI
2M ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
Premium
Ratings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
2M ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
Premium
Ratings
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
2M ago
SVRA
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
PremiumThe Fly
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
2M ago
BX
MS
Savara Signs Long-Term Lease for New Headquarters
PremiumCompany Announcements
Savara Signs Long-Term Lease for New Headquarters
2M ago
8K
SVRA
Savara reports Q4 EPS (13c), consensus (12c)
PremiumThe Fly
Savara reports Q4 EPS (13c), consensus (12c)
2M ago
SVRA
Savara announces receipt of Day 74 Letter from FDA
PremiumThe Fly
Savara announces receipt of Day 74 Letter from FDA
2M ago
SVRA
Savara says FDA files BLA for Molbreevi
PremiumThe FlySavara says FDA files BLA for Molbreevi
3M ago
SVRA
Savara announces BLA for Molbreevi filed for review by FDA
Premium
The Fly
Savara announces BLA for Molbreevi filed for review by FDA
3M ago
SVRA
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
Premium
Company Announcements
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
3M ago
SVRA
Savara Enters New Material Definitive Agreement and Obligation
PremiumCompany Announcements
Savara Enters New Material Definitive Agreement and Obligation
4M ago
8K
SVRA
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
PremiumRatings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
4M ago
SVRA
Savara Highlights Autoimmune PAP Burden in Updated Presentation
PremiumCompany Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
4M ago
8K
SVRA
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
PremiumRatings
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
5M ago
SVRA
Savara price target raised to $10 from $8 at H.C. Wainwright
PremiumThe FlySavara price target raised to $10 from $8 at H.C. Wainwright
5M ago
SVRA
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
Premium
Ratings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
5M ago
SVRA
Savara resubmits Molbreevi BLA to the FDA
Premium
The Fly
Savara resubmits Molbreevi BLA to the FDA
5M ago
SVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >